The use of HeberFERON in patients with basal-cell carcinoma treated in the municipality of Puerto Padre, Las Tunas

Authors

  • Daniel V. Drake-Sosa Hospital General Docente "Guillermo Domínguez López". Puerto Padre, Las Tunas. Universidad de Ciencias Médicas de Las Tunas. Las Tunas
  • Leonides Rojas-Barlys Hospital General Docente "Guillermo Domínguez López". Puerto Padre, Las Tunas. Universidad de Ciencias Médicas de Las Tunas. Las Tunas

Keywords:

BASAL CELL CARCINOMA, SKIN NEOPLASMS, THERAPEUTICS.

Abstract

Background: Basal-cell carcinoma can be treated with different methods, depending on the clinical variant, location and size of the lesion. There is a history of the successful use of HeberFERON as a therapeutic alternative for this type of carcinoma.

Objective: to assess the effectiveness of HeberFERON in patients with basal-cell carcinoma who visited the dermatology department of the “Guillermo Domínguez López” General Teaching Hospital of Puerto Padre, Las Tunas, from October 2017 to April 2018.

Methods: an observational, descriptive, cross-sectional study was carried out with 9 patients diagnosed with basal-cell carcinoma, treated at the aforementioned institution and during the period herein declared. The histological type of the tumor was identified. The patients were administered the medication by perilesional infiltration or intramuscular injection, according to the size of the tumor, number of lesions and the grade of the actual actinic damage.

Results: 33,3 % of the patients presented basal-cell carcinoma of the nodular subtype and an equal number presented the squamous subtype. Six patients (66,7 %) received treatment through perilesional infiltration. A total cure in five patients (55,6 %) was achieved, three had a partial healing and one had to be interrupted due to adverse reactions. All the patients showed general secondary reactions to treatment as fever, general malaise, fatigue and arthralgia.

Conclusions: HeberFERON proved to be effective for the treatment of basal-cell carcinoma in the studied patients, mainly for those with not much actinic damage and only one lesion.

Downloads

Download data is not yet available.

Author Biographies

Daniel V. Drake-Sosa, Hospital General Docente "Guillermo Domínguez López". Puerto Padre, Las Tunas. Universidad de Ciencias Médicas de Las Tunas. Las Tunas

Especialista de Segundo Grado en Dermatología. Investigador Agregado. Profesor Asistente

Leonides Rojas-Barlys, Hospital General Docente "Guillermo Domínguez López". Puerto Padre, Las Tunas. Universidad de Ciencias Médicas de Las Tunas. Las Tunas

Especialista de Primer Grado en Dermatología. Profesor Asistente

References

Güémez-Graniel MF, Plascencia-Gómez A, Graniel-Lavadores MJ, Dzul-Rosado K. Epidemiología del cáncer de piel en el Centro Dermatológico de Yucatán durante 2012. Dermatol Rev Mex [revista en internet]. 2015 [citado 7 de febrero 2018]; 59(1): 9-18. Disponible en: http://www.medigraphic.com/cgi-bin/new/ resumen.cgi?IDARTICULO=54991.

Gandhi SA, Kampp J. Skin cancer epidemiology, detection and management. Med Clin North Am. [revista en internet]. 2015 [citado 7 de febrero 2018]; 99(6): 1323-1335. Disponible en: https://www.medical.the clinics.com/article/S0025-7125(15)00101-7/abstract.

Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs. [revista en internet]. 2013 [citado 7 de febrero 2018]; 29(3): 160-169. Disponible en: https://www.sciencedirect.com/ science/article/pii/S0749208113000326.

Ibrahim O, Gastman B, Zhang A. Advances in diagnosis and treatment of nonmelanoma skin cancer. Ann Plast Surg. [revista en internet]. 2014 [citado 7 de febrero 2018]; 73(5): 615-619. Disponible en: https://journals.lww.com/annalsplasticsurgery/fulltext/2014/11000/Advances_in_Diagnosis_and_Treatment_of_Nonmelanoma.29.aspx.

Dirección de Investigaciones Clínicas. Informe Periódico de Seguridad del HeberPAG. La Habana: Dirección de Investigaciones Clínicas. Centro de Ingeniería Genética y Biotecnología; 2013.

Nova J, Patiño A, González A. Caracterización de la población con carcinoma basocelular en el Centro Dermatológico Federico Lleras Acosta. Rev CES Med [revista en internet]. 2014 [citado 7 de febrero 2018]; 28(2): 177-184. Disponible en: http://revistas.ces.edu.co/index.php/medicina/article/view/2885.

Metterle L, Nelson C, Patel N. Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review. J Am Acad Dermatol. [revista en internet]. 2016 [citado 7 de febrero 2018]; 74(3): 552-557. Disponible en: https://www.sciencedirect.com/science/article/pii/S0190962215022458.

Bahner JD, Bordeaux JS. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, iquimod, diclofenac, or what? Facts and controversies. Clin Dermatol. [revista en internet]. 2013 [citado 7 de febrero 2018]; 31(6): 792-798. Disponible en: https://www.sciencedirect.com/science/article/pii/S07380 81X13001703.

Rong Y, Zuo L, Shang L, Bazan JG. Radiotherapy treatment for nonmelanoma skin cancer. Expert Rev Anticancer Ther. [revista en internet]. 2015 [citado 7 de febrero 2018]; 15(7): 765-776. Dispopnible en: https://www.tandfonline.com/doi/abs/10.1586/14737140.2015.1042865.

Divine J, Stefaniwksy L, Reddy R, Padilla P, Hagele T, Patel NS, et al. A comprehensive guide to the surgical management of nonmelanoma skin cancer. Curr Probl Cancer. [revista en internet]. 2015 [citado 7 de febrero 2018]; 39(4): 216-225. Disponible en: https://www.jaad.org/article/S0147-0272(15)00053-7/ abstract.

Villarreal-Martínez A, Ocampo-Candiani J. Técnicas actuales para el diagnóstico del carcinoma basocelular: dermatoscopia y microscopia de reflectancia confocal. Dermatol Rev Mex [revista en internet]. 2015 [citado 7 de febrero 2018]; 59(2): 129-135. Disponible en: http://www.medigraphic.com/cgi-bin/new/ resumen.cgi?IDARTICULO=56729.

Rojas Rondón I, Duncan Roberts Y, Gómez Cabrera CG, Ramírez García LK, Vigoa Aranguren L, Hernández Rodríguez R, et al. Administración del HeberFERON en el carcinoma basocelular palpebral a propósito de 2 casos. Bionatura [revista en internet]. 2016 [citado 7 de febrero 2018]; 1(2). Disponible en: http://revistabionatura.com/files/Administracion-del-HeberFERON-en-el-carcinoma-basocelular.pdf.

Fernández-Martori M, Bello-Rivero I, Duncan-Roberts Y. Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care. MEDICC Review [revista en internet]. 2018 [citado 7 de febrero 2018]; 20(1). Disponible en: http://www.medigraphic.com/pdfs/medicreview/mrw-2018/mrw181e.pdf.

Downloads

Published

2018-09-27

How to Cite

1.
Drake-Sosa DV, Rojas-Barlys L. The use of HeberFERON in patients with basal-cell carcinoma treated in the municipality of Puerto Padre, Las Tunas. Rev. electron. Zoilo [Internet]. 2018 Sep. 27 [cited 2025 Sep. 17];43(6). Available from: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/1573

Issue

Vol. 43 No. 6 (2018): November-December

Section

Original articles

License

This journal provides free and immediate access to its content under the principle that making research freely available to the public supports a greater exchange of global knowledge. This means that the authors transfer the copyright to the journal, so that copies and distribution of the contents can be made by any means, as long as the authors' acknowledgment is maintained. These terms are a reflection that the journal assumes copyright under Creative Commons licenses, specifically under a Creative Commons Attribution 4.0 International license.

Registration and submission of articles to the journal is free. The processing, including review, editing and publication, is completely free of charge.